



NDA 21-455

Hoffmann-La Roche Inc.  
Attention: Mark Hope  
Regulatory Program Director  
340 Kingsland Street  
Nutley, NJ 07110

Dear Mr. Hope:

Please refer to your new drug application (NDA) dated July 15, 2002, received July 16, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Boniva (ibandronate sodium) Tablets.

We acknowledge receipt of your submissions dated September 4, 5, and 20, November 15 and 18, and December 11 and 20, 2002, and January 9, 17, 20, and 31, February 12, 21(2), 25, 26, and 28(2), March 6, 14, 19, 21, 24, and 28, April 9, 29, and 30, and May 5, 7, 9, and 16, 2003.

This new drug application provides for the use of Boniva (ibandronate sodium) Tablets for the treatment and prevention of postmenopausal osteoporosis.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed-upon labeling text. Accordingly, the application is approved effective on the date of this letter.

Sufficient stability data has been submitted to support a 36-month expiration date.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert, patient package insert, and container labels submitted May 16, 2003). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-455." Approval of this submission by FDA is not required before the labeling is used.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to the Division of Metabolic and Endocrine Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products. You should refer to the Guidance for Industry on Qualifying for Pediatric Exclusivity (available on our web site at [www.fda.gov/cder/pediatric](http://www.fda.gov/cder/pediatric)) for details. If you wish to qualify for pediatric exclusivity you should submit a "Proposed Pediatric Study Request." FDA generally does not consider studies submitted to an NDA before issuance of a Written Request as responsive to the Written Request. Applicants should obtain a Written Request before submitting pediatric studies to an NDA.

Please cite the NDA number listed above at the top of the first page of any communications concerning this application. Address all communications concerning this NDA as follows:

U.S. Postal/Courier/Overnight Mail:  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Metabolic and Endocrine Drug Products, HFD-510  
Attention: Fishers Document Room  
5600 Fishers Lane  
Rockville, Maryland 20857

NDA 21-455

Page 3

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

*{See appended electronic signature page}*

Robert Meyer, M.D.  
Director  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Robert Meyer

5/16/03 03:07:03 PM